Stemline Therapeutics Inc (STML) CEO Sells $77,588.00 in Stock

Stemline Therapeutics Inc (NASDAQ:STML) CEO Ivan Bergstein sold 6,800 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $11.41, for a total transaction of $77,588.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Ivan Bergstein also recently made the following trade(s):

Get Stemline Therapeutics alerts: On Monday, February 25th, Ivan Bergstein sold 22,905 shares of Stemline Therapeutics stock. The shares were sold at an average price of $12.03, for a total transaction of $275,547.15. On Thursday, February 14th, Ivan Bergstein sold 34,132 shares of Stemline Therapeutics stock. The shares were sold at an average price of $10.98, for a total transaction of $374,769.36.

STML stock traded up $0.60 during mid-day trading on Friday, reaching $11.62. 1,108,432 shares of the stock traded hands, compared to its average volume of 720,218. Stemline Therapeutics Inc has a 52-week low of $7.82 and a 52-week high of $20.55. The firm has a market capitalization of $368.89 million, a PE ratio of -3.95 and a beta of 1.12.

STML has been the subject of a number of analyst reports. Piper Jaffray Companies upped their price objective on shares of Stemline Therapeutics to $30.00 and gave the company an “overweight” rating in a research note on Wednesday, December 26th. Roth Capital set a $33.00 price objective on shares of Stemline Therapeutics and gave the company a “buy” rating in a research note on Sunday, December 23rd. ValuEngine lowered shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 3rd. JPMorgan Chase & Co. initiated coverage on shares of Stemline Therapeutics in a research note on Tuesday, December 11th. They set an “overweight” rating and a $17.00 price objective for the company. Finally, BidaskClub lowered shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 29th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Stemline Therapeutics has a consensus rating of “Buy” and a consensus price target of $25.40.

A number of hedge funds have recently bought and sold shares of the business. Great West Life Assurance Co. Can acquired a new position in shares of Stemline Therapeutics in the 4th quarter valued at about $47,000. Legal & General Group Plc increased its holdings in shares of Stemline Therapeutics by 27.1% in the 4th quarter. Legal & General Group Plc now owns 5,249 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 1,120 shares during the period. Metropolitan Life Insurance Co. NY increased its holdings in shares of Stemline Therapeutics by 327.0% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 8,523 shares of the biopharmaceutical company’s stock valued at $81,000 after purchasing an additional 6,527 shares during the period. Bank of America Corp DE increased its holdings in shares of Stemline Therapeutics by 56.8% in the 4th quarter. Bank of America Corp DE now owns 10,669 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 3,866 shares during the period. Finally, Janney Montgomery Scott LLC acquired a new position in shares of Stemline Therapeutics in the 4th quarter valued at about $108,000. 66.28% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Stemline Therapeutics Inc (STML) CEO Sells $77,588.00 in Stock” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/4207663/stemline-therapeutics-inc-stml-ceo-sells-77588-00-in-stock.html.

About Stemline Therapeutics

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

Featured Story: What is the Dividend Aristocrat Index?